Application of artesunate in preparation of medicines for treating infantile hemangioma

Abstract

The invention discloses an application of artesunate in the preparation of medicines for treating infantile hemangioma. The medicines can fundamentally treat the hemangioma from the pathogenesis against hemangioma forming pathologic mechanisms, have small side effects, do not cause local embolism or severe necrosis of normal tissues, and can obviously reduce the clinic treatment cost because of the low price of the artesunate.

Description

Technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of artesunate in the preparation of medicines for treating infantile hemangiomas. Background technique [0002] Hemangioma is a common congenital abnormality of vascular development in infants and young children. The incidence of hemangioma in infants and young children is 10%-12%. The incidence rate is high. Currently, there are various clinical treatment methods. In the study of infantile hemangioma, Dan xu et al. found that SALL4+ and CD133 were highly expressed in hemangioma cells in the proliferating phase than in the hemangioma cells in the regressing phase, confirming that hemangiomas have stem cell characteristics. Damian Medici found in the research on the mechanism of rapamycin in the treatment of proliferative hemangioma that rapamycin can inhibit the proliferation of vascular endothelial cells by inhibiting the mTOR pathway and reducing the expressi...

AI Technical Summary

Problems solved by technology

[0003] There are many means of clinical treatment of hemangioma in children. The current status and shortcomings of hemangioma treatment, such as 1. Hormone therapy: including oral administration and local injection, can achieve exact results. Disadvantages: ① induce or aggravate local infection ② substance metabolism and water-salt Metabolic disorders Long-term use of glucocorticoids in large quantities can cause substance metabolism and water-salt metabolism disorders, adrenal hyperfunction syndrome, ③ cardiovascular system complications, long-term use of glucocorticoids, because it can lead to sodium, water retention and blood lipids High, can induce hypertension and atherosclerosis

2. The exact mechanism of propranolol oral treatment is not yet clear

Disadvantages: During the treatment process, it is necessary to closely observe the changes in the heart function and blood sugar of the child, and the drug should be discontinued if the following points occur: ① Bradycardia or heart rate drops below 70% of the heart rate value in the awake state of children of the same age; ② Hypotension symptoms or blood pressure drop The blood pressure value is more than 25% higher than that of children of the same age in awake state; ③ hypoglycemia symptoms; ④ wheezing or dyspnea

[0004] Disadvantages of sclerosing agent injection therapy: severe pain during local injection, which may cause a wide range of tissue necrosis and ulceration, eventually forming scars, and occasionally severe allergic reactions

Its main disadvantages: adverse reactions mainly include fever, gastrointestinal reactions (nausea, vomiting, loss of appetite, etc.), skin reactions (pigmentation, thickened keratosis, dermatitis, rash, etc.), hair loss, limb paralysis and oral inflammation, etc. , lung pneumonia-like lesions or pulmonary fibrosis, etc. And there is a paradox in the application of anticancer drugs to the treatment of hemangiomas (non-true tumors) 5. Laser therapy: CO2 laser and YAG laser treatment of hemangiomas due to the penetration depth of light energy Limited, cannot effectively control hemangioma growth, and tends to leave hypopigmented scars

[0005] There is no unified treatment standard in terms of treatment, and various treatment methods lack a certain theoretical basis. Some injection drugs such as the hormone triamcinolone acetonide and the anticancer drug Pingyangmycin are difficult to evaluate for long-term side effects

Artemisinin drugs have been used in the clinical treatment of malaria for decades, and are relatively mature clinical drugs. No serious systemic and local adverse reactions have been found so far. However, artesunate has not been used in the prior art. in children with hemangioma